- EGFR Signaling Pathway
- TGF-beta Signaling
- Canonical Wnt Signaling
- non-Canonical Wnt Signaling
- Notch Signaling
- p53 Pathway
- NF-kB Pathway
- Cytokine Signaling
>Human Cell Expressed
>Cynomolgus IGFBP3 Protein (His Tag)
|Catalog||Size (Price)||Quantity||In Stock||Operation|
Insulin-like growth factor binding protein 3 Protein Datasheet
IGFBP3 Protein Price Inquiry ( Available Sizes )
IGFBP3 Protein Product Information
A DNA sequence encoding the cynomolgus IGFBP3(Gly28-Lys291) was expressed with a polyhistide tag at the N-terminus.
|Expression Host:||Human Cells|
IGFBP3 Protein QC Testing
|Purity:||> 95 % as determined by SDS-PAGE||SDS-PAGE:
|Measured by its ability to inhibit the biological activity of IGFI or IGFII on MCF7 human breast adenocarcinoma cells (Karey, K.P. et al. (1988) Cancer Research 48:4083.).
The ED50 for this effect is typically 0.15-0.75 μg/mL in the presence of 14 ng/mL human IGFII.
|Endotoxin:||< 1.0 EU per μg of the protein as determined by the LAL method|
|Stability:||Samples are stable for up to twelve months from date of receipt at -70℃|
|Predicted N terminal:||His|
The recombinant heterodimer of cynomolgus IGFBP3 comprises 284 amino acids and has a calculated molecular mass of 31.1 KDa. The apparent molecular mass of the protein is approximately 41-44 KDa respectively in SDS-PAGE.
|Formulation:||Lyophilized from sterile PBS, pH 7.4.
IGFBP3 Protein Usage Guide
|Storage:||Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|Reconstitution:||A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.|
IGFBP3 Protein Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|IGFBP3||Human||IGFBP3 Protein, Recombinant||10430-H07H|
|IGFBP3||Cynomolgus||IGFBP3 Protein, Recombinant||90084-C07H|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|WB, ELISA||Mouse Monoclonal Antibody||10430-MM01|
|WB, ELISA||IGFBP3 Antibody||10430-RP01|
|WB, ELISA||IGFBP3 Antibody (Antigen Affinity Purified)||10430-RP02|
|WB, ELISA||IGFBP3 Antibody||10430-R008|
IGFBP3 Protein Description
Insulin-like growth factor-binding proteins (IGFBPs) prolong the half-life of the IGFs, control bioavailability, activity, and distribution of insulin-like growth factor (IGF) through high-affinity IGFBP/IGF complexes. Six high-affinity IGF-binding proteins (IGFBP-1 to -6) have been identified. Human IGFBP3 is a widely expressed protein containing an IGFBP domain at the N-terminus and a thyroglobulin type-I domain. IGFBP3 forms a ternary complex of about 140 ~150 kDa with IGF1 or IGF2 and a glycoprotein insulin-like growth factor acid-labile subunit (ALS), thus alter the interaction of IGFs with their cell surface receptors. IGFBP3 exerts either proapoptotic or growth stimulatory effects depending upon the cellular context. Studies have shown that IGFBP3 can leads to the induction of apoptosis dependent or independent of the IGF-IGF receptor axis, accordingly acts as a negative regulator of tumorigenesis and progressing in certain carcinomas. In addition, IGFBP3 also interacts with the Alzheimer's survival peptide humanin (HN), playing a role in neurological disease processes.
- Cubbage ML. et al., 1990, J Biol Chem. 265: 12642-9.
- Ikonen M. et al., 2003, Proc Natl Acad Sci. 100: 130428-47.
- Kim HS. et al., 2004, Cancer Res. 64: 2229-37.
- Hong J. et al., 2002, J Biol Chem. 277: 10488-97.